How important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: a French study
- 22 January 2007
- journal article
- review article
- Published by Wiley in Prenatal Diagnosis
- Vol. 27 (3) , 197-205
- https://doi.org/10.1002/pd.1656
Abstract
Objectives To evaluate the level of information and informed consent for maternal serum screening (MSS) for Down syndrome (DS) in the second trimester of pregnancy and analyse the exercise of autonomy towards the test by the women concerned. Methods We studied the population of pregnant women attending obstetric consultations in two French hospitals over a 3-month period. The women were assigned to three groups according to MSS results for DS: women at high risk of having a child with DS (group 1), women at low risk (group 2) and women who did not undergo the test (group 3). A questionnaire was completed before the medical consultation, to assess the quality of consent before amniocentesis for the group at high risk and before the second-trimester ultrasound scan for the other two groups. Results We analysed 305 questionnaires for 89, 137 and 79 women belonging to groups 1, 2 and 3 respectively. In total, 123 women (40.3% [IC 95%, 35–46%]) were considered to be well informed; 33 (10%, [IC 95%, 8–12%]) had a high level of knowledge, but made choices not consistent with their stated attitude, and 149 (49.7% [IC 95%, 45–56%]) were considered uninformed. Logistic regression analysis showed that maternal consent depended on three independent components: The score attributed to the doctor for information about MSS (t = 4.216, p < 0.001). Whether the patient belonged to group 1 (t = −2.631, p < 0.009). Educational level (< high-school diploma, high-school diploma or at least two years of higher education after high school) (t = 2.324, p < 0.02). The rate of consent increased with educational level and was highest for the women in group 1 and for those whose doctor had a high information score. Conclusions Our findings clearly show that women are provided with insufficient information concerning MSS screening for DS in the second trimester of pregnancy for real and valid consent to be obtained. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 15 references indexed in Scilit:
- Uptake of a prenatal screening test: the role of healthcare professionals' attitudes towards the testPrenatal Diagnosis, 2004
- La mesure de la clarté nucale et le dosage des marqueurs sériques commencent-ils à modifier l'incidence de la trisomie 21 en France ?Gynécologie Obstétrique & Fertilité, 2004
- Effects of maternal age and education on the pattern of prenatal testing: Implications for the use of antenatal screening as a solution to the growing number of amniocentesesAmerican Journal of Obstetrics and Gynecology, 2003
- Informed choice: understanding knowledge in the context of screening uptakePatient Education and Counseling, 2003
- A measure of informed choiceHealth Expectations, 2001
- Existence and quality of written antenatal screening policies in the United Kingdom: postal surveyBMJ, 2001
- How Doctors and Patients Discuss Routine Clinical Decisions Informed Decision Making in the Outpatient SettingJournal of General Internal Medicine, 1997
- Serum screening for Down's syndrome: how much do health professionals know?BJOG: An International Journal of Obstetrics and Gynaecology, 1997
- Informed consent to undergo serum screening for Down's syndrome: the gap between policy and practiceBMJ, 1994
- Serum screening for Down's syndrome: experiences of obstetricians in England and WalesBMJ, 1994